Rana R. McKay, MD, presented “Overall Survival with Sipuleucel-T in Patients Treated for Advanced Prostate Cancer” for the Grand Rounds in Urology audience in December 2020.
How to cite: McKay, Rana R. “Overall Survival with Sipuleucel-T in Patients Treated for Advanced Prostate Cancer” December 2020. Accessed Dec 2025. https://grandroundsinurology.com/overall-survival-with-sipuleucel-t-in-patients-treated-for-advanced-prostate-cancer/
Summary:
Rana R. McKay, MD, Associate Professor of Medicine at the University of California, San Diego, and Co-Leader of the Genitourinary Oncology Disease Team at the Moores Cancer Center, discusses the results of a real-world analysis examining survival outcomes in Medicare beneficiaries with metastatic castrate-resistant prostate cancer (mCRPC) who were treated with sipuleucel-T and more recently-approved novel hormonal agents in a real-world treatment setting. Dr. McKay explains that findings show that, for the population studied, use of sipuleucel-T and oral agent results in a statistically significant improvement in overall survival and reduction in mortality compared to patients who never received sipuleucel-T, regardless of when it was given. Following her presentation, E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology, conducts a Q&A session with Dr. McKay in which they discuss the increasing acceptance of sipuleucel-T among medical oncologists, how complementary MOAs may improve patient outcomes, and the future of sipuleucel-T, among other clinical topics.
ABOUT THE AUTHOR
Rana R. McKay, MD, FASCO, is a Professor of Medicine and Urology at the University of California, San Diego, and co-leader of the Genitourinary Oncology Disease Team at the Moores Cancer Center. Dr. McKay specializes in treating people with urogenital cancers, including bladder, kidney, prostate, and testicular cancer. Her research interests include the design and implementation of clinical trials to advance the treatment of patients with urologic cancers.
